Immunology Clinical Trials Update: Week 13, 2026

Published March 29, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Opioid, HIV and Immune System

This study from the University of Miami looks at how opioid use affects the immune response to the flu vaccine in people with and without HIV. Since both HIV and opioid use can impact the immune system, understanding these effects may lead to better vaccine strategies for those whose immune systems are weakened by these factors. The trial is not currently recruiting but is actively analyzing blood samples to learn more about immune responses.

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

Sponsored by the National Institute of Allergy and Infectious Diseases, this phase 2 trial aims to improve how milk and peanut allergies are diagnosed in children and young adults with eczema. By using detailed food challenges and blood tests, the study hopes to identify more accurate allergy thresholds. This could help patients avoid unnecessary food restrictions and better manage their allergies. The trial is currently recruiting children and young adults aged 3 to 21 in the United States.

NIAID Centralized Sequencing Protocol

This study investigates the use of genetic sequencing to better understand immune-related conditions like atopy, primary immunodeficiency, autoimmunity, and autoinflammation. By identifying important genetic factors, the research could lead to more personalized care in the future. The study is recruiting participants of all ages across the United States, including family members of current participants.

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

This phase 1 trial is testing a new cell therapy called Descartes-08 for young people with autoimmune diseases such as childhood-onset lupus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis. If effective and safe, this treatment may provide a new option for managing these difficult conditions in children and young adults. The study is currently recruiting up to 50 participants in the United States.

SHAPE Pilot Trial: Skin Health and Allergy Prevention Exposure

This Canadian study tests a package of environmental steps designed to prevent food allergies in infants who are at risk. The trial focuses on early-life interventions and will follow infants through their first year to see if these measures reduce the chance of developing food allergies. The study is currently recruiting families in Canada and involves simple home-based actions and regular follow-up visits.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.